That's accurate however worth noting Telix (ASX:TLX) has a...

That's accurate however worth noting Telix (ASX:TLX) has a single imaging agent commercialised and is at a $2.3 billion market cap. That's for men with prostate cancer. The other point to note is that the same targeting agents that are developed as imaging agents (if specific enough) can be used as therapeutics too by attaching the radioactive isotope in basic terms. The good thing about imaging too is speed and cost of trials as well as an accelerated approval timeline.. ASX won't care until it does. That'll probably be sometime in 2023 once the post raise indigestion has cleared, more trials commence and or partnerships announced.